Analyses / Whip Count Analysis / 119 · HR 5791 Whip Count Analysis

119-HR-5791 DC Insider Whip Count Analysis

119 · HR 5791 BLOOD Centers Act

health_and_safety Health

House Republicans control the chamber and Energy & Commerce, and the Senate is GOP‑run under Thune; the bill’s narrow, technical scope plus visible backing from the blood‑center sector position it well for bipartisan movement in committee and potential House passage under suspension, though shutdown timing and FDA staffing turmoil complicate floor windows and agency views. Overall odds to become law in the 119th: moderate, with the cleaner path as an add‑on to a larger health vehicle. [1]Wikipedia — 119th United States Congress - Wikipedia[2]AP News — US Rep. Brett Guthrie to lead House Energy and Commerce Committee[3]House Energy & Commerce Committee (Republicans) — Chairman Guthrie Announces 11…[4]America’s Blood Centers — Modernizing the Licensure Process - America’s Blood C…

Analyzed as
DC Insider
Published
18 Oct 2025
Updated
18 Oct 2025
Tags
whip-count · health-policy · FDA
Unvetted
01 · Section

Breakdown: expected support and opposition

Institutional control this Congress favors movement of narrow FDA process bills, but floor timing is tight and Senate clearance still requires either unanimous consent or 60 votes absent a time agreement. [1]Wikipedia — 119th United States Congress - Wikipedia[5]Congressional Research Service (Congress.gov) — CRS: The Legislative Process on…

  • House baseline: GOP majority with Speaker Johnson and E&C chaired by Brett Guthrie; Health Subcommittee chaired by Buddy Carter. Expect near‑uniform Republican support in committee and on the floor; Democratic support is available from moderates and members engaged on blood policy (e.g., Schrier, the bill’s Democratic co‑sponsor). [1]Wikipedia — 119th United States Congress - Wikipedia[2]AP News — US Rep. Brett Guthrie to lead House Energy and Commerce Committee[3]House Energy & Commerce Committee (Republicans) — Chairman Guthrie Announces 11…[6]Congress.gov — Rep. Kim Schrier — Congress.gov profile
  • House procedure expectation: likely scheduled under Suspension of the Rules (no floor amendments; two‑thirds required). That path generally signals broad bipartisan support for technical bills. [7]Congressional Research Service (Congress.gov) — CRS: Suspension of the Rules in…
  • House Democratic blocs: E&C Democrats led by Ranking Member Frank Pallone and Health Subcommittee RM Diana DeGette may support with guardrails; progressive skeptics could object if framed as weakening safety review, but the text preserves FDA denial authority for safety/purity/potency. [8]Office of Rep. Diana DeGette — DeGette announced as Top Democrat on E&C Health…
  • Interest‑group signaling: America’s Blood Centers and AABB have been pressing to "cut red tape" and streamline licensure; no organized consumer‑safety coalition has publicly mobilized against this narrow change to date. That points to bipartisan comfort if technical concerns are addressed in report language. [4]America’s Blood Centers — Modernizing the Licensure Process - America’s Blood C…[9]Web search · turn 7 #4[10]AABB — AABB Regulatory Update: BLA checklist for apheresis plasma (supplements…
  • Senate baseline: GOP majority; HELP chaired by Bill Cassidy with Sanders as RM. HELP Republicans likely favorable to streamlining; Democrats will scrutinize the 30‑day clock but may accept with explicit safety carve‑outs already in the bill. Final passage will need either a hotline/UC or a 60‑vote cloture path. [1]Wikipedia — 119th United States Congress - Wikipedia[11]Senate HELP Committee (Republicans) — Cassidy seated as Chair of Senate HELP Co…[5]Congressional Research Service (Congress.gov) — CRS: The Legislative Process on…
  • Administration context: FDA/HHS workforce and policy turbulence (RIFs, reorganizations, and expedited initiatives elsewhere) create mixed signals—political appetite for "speed" but real capacity constraints at FDA that could spur behind‑the‑scenes reservations about a statutory 30‑day mandate. [12]STAT News — STAT: HHS job cuts include 3,500 FDA layoffs[13]AP News — FDA unveils expedited review list under National Priority Voucher pro…
02 · Section

Key legislators and pivotal swing votes

Focus on chairs, floor leaders, and cross‑pressured members with health portfolios or industry footprint.

  • House advocates: Sponsor Tony Wied (WI‑08); co‑sponsors Tom Tiffany (WI‑07) and Kim Schrier (WA‑08). Bipartisan sponsor slate helps with Suspension optics. [14]Wikipedia — Tony Wied - Wikipedia[15]Wikipedia — Tom Tiffany - Wikipedia[6]Congress.gov — Rep. Kim Schrier — Congress.gov profile
  • House gatekeepers: E&C Chair Brett Guthrie (full committee) and Health Subcommittee Chair Buddy Carter control hearings/markups; DeGette as Health RM can negotiate technical tweaks to secure Democratic votes. [2]AP News — US Rep. Brett Guthrie to lead House Energy and Commerce Committee[3]House Energy & Commerce Committee (Republicans) — Chairman Guthrie Announces 11…[8]Office of Rep. Diana DeGette — DeGette announced as Top Democrat on E&C Health…
  • House floor: Speaker Mike Johnson and Majority Leader Steve Scalise set floor windows; ongoing shutdown brinkmanship has delayed even routine matters. Expect leadership to bunch low‑controversy suspensions when the chamber reopens fully. [16]Politico — Johnson refuses to swear in Grijalva amid shutdown standoff[17]Office of the House Majority Leader — Scalise statement on being re‑elected Hou…
  • Senate gatekeepers: HELP Chair Bill Cassidy (R‑LA) and RM Bernie Sanders (I‑VT). Cassidy’s posture toward HHS has been assertive oversight; he’s positioned to broker a narrow process fix if FDA signals feasibility. [11]Senate HELP Committee (Republicans) — Cassidy seated as Chair of Senate HELP Co…
  • Senate floor: Majority Leader John Thune controls hotline/UC strategy; he has publicly kept the filibuster, so absent UC the functional bar is 60. [5]Congressional Research Service (Congress.gov) — CRS: The Legislative Process on…[18]New York Post — GOP leader John Thune vows to preserve filibuster as Republican…
03 · Section

Leadership stance and procedural dynamics

This is a low‑cost process bill; success depends more on agenda time and staff capacity than on ideology.

  • Committee landscape: House E&C (Guthrie) and Subcommittee on Health (Carter) have jurisdiction; Democrats’ Health RM DeGette has signaled willingness to engage on health systems issues this Congress. That alignment favors a quick subcommittee hearing and full‑committee markup. [2]AP News — US Rep. Brett Guthrie to lead House Energy and Commerce Committee[3]House Energy & Commerce Committee (Republicans) — Chairman Guthrie Announces 11…[8]Office of Rep. Diana DeGette — DeGette announced as Top Democrat on E&C Health…
  • House floor paths: Most efficient is Suspension of the Rules—no amendments; two‑thirds threshold. If that falters or timing slips amid the shutdown, a structured rule is a fallback but consumes scarce floor time. [7]Congressional Research Service (Congress.gov) — CRS: Suspension of the Rules in…
  • Senate paths: Best case is hotline and UC passage if the House sends a clean, bipartisan bill with supportive committee report language; otherwise, HELP markup plus a short floor agreement with limited amendments and a 60‑vote threshold. [5]Congressional Research Service (Congress.gov) — CRS: The Legislative Process on…[19]Web search · turn 11 #0
  • Context at FDA/HHS: AABB and ABC materials document delays and duplicative filings for adding apheresis sites under 21 CFR 601.12; simultaneous RIF/reorg at HHS and FDA could make a hard 30‑day clock operationally sensitive, prompting FDA technical asks (e.g., comparability protocol language in committee report). [20]U.S. Food & Drug Administration — FDA Guidance: Changes to an Approved Applicat…[10]AABB — AABB Regulatory Update: BLA checklist for apheresis plasma (supplements…[12]STAT News — STAT: HHS job cuts include 3,500 FDA layoffs
04 · Section

Assessment: likelihood of passage

Bottom‑line whip and timing view from a process perspective.

  • House committee: High likelihood to report with bipartisan votes given chair/ranking alignment and sector support; expect technical manager’s amendment clarifying safety carve‑outs and eligibility criteria. [3]House Energy & Commerce Committee (Republicans) — Chairman Guthrie Announces 11…[8]Office of Rep. Diana DeGette — DeGette announced as Top Democrat on E&C Health…[4]America’s Blood Centers — Modernizing the Licensure Process - America’s Blood C…
  • House floor: Moderate‑to‑high likelihood under Suspension once the chamber returns to regular business; shutdown and leadership leverage games are the main near‑term risk. [7]Congressional Research Service (Congress.gov) — CRS: Suspension of the Rules in…[16]Politico — Johnson refuses to swear in Grijalva amid shutdown standoff
  • Senate: Moderate likelihood—best as a UC add‑on to a health package or as a hotline of the House‑passed bill; freestanding consideration would still need 60 if any objection arises. [5]Congressional Research Service (Congress.gov) — CRS: The Legislative Process on…
  • Overall enactment (119th Congress): Moderate. Cleanest route is attachment to a broader health extenders/FDA technical package where there’s bipartisan appetite and minimal score. Sector advocacy is ongoing, and the bill’s built‑in safety/purity/potency override reduces ideological friction. [9]Web search · turn 7 #4
House floor threshold under Suspension
66.7percent of Members present/voting
Senate cloture threshold (if no UC)
60votes
Statutory review clock in bill
30days
FDA layoffs proposed in 2025 reorg
3500positions
Blood donation sites nationwide (ABC)
800plus
05 · Section

Sourcing (selected)

Core facts and procedural references are drawn from official committee/leadership pages, CRS primers, FDA guidance, and major outlets.

  • Chamber control and leadership for the 119th Congress. [1]Wikipedia — 119th United States Congress - Wikipedia
  • House Energy & Commerce: chair and Health Subcommittee roster; Health RM announcement. [2]AP News — US Rep. Brett Guthrie to lead House Energy and Commerce Committee[3]House Energy & Commerce Committee (Republicans) — Chairman Guthrie Announces 11…[8]Office of Rep. Diana DeGette — DeGette announced as Top Democrat on E&C Health…
  • Senate HELP leadership. [11]Senate HELP Committee (Republicans) — Cassidy seated as Chair of Senate HELP Co…
  • House Suspension of the Rules primer (CRS). [7]Congressional Research Service (Congress.gov) — CRS: Suspension of the Rules in…
  • Senate unanimous consent/filibuster mechanics (CRS). [5]Congressional Research Service (Congress.gov) — CRS: The Legislative Process on…
  • FDA change‑control guidance for licensed blood products; AABB/ABC materials on BLA supplements and licensure delays. [20]U.S. Food & Drug Administration — FDA Guidance: Changes to an Approved Applicat…[10]AABB — AABB Regulatory Update: BLA checklist for apheresis plasma (supplements…[4]America’s Blood Centers — Modernizing the Licensure Process - America’s Blood C…
  • Shutdown‑related floor/timing constraints; HHS/FDA workforce reductions. [16]Politico — Johnson refuses to swear in Grijalva amid shutdown standoff[12]STAT News — STAT: HHS job cuts include 3,500 FDA layoffs
  • Bill sponsors’ current status. [14]Wikipedia — Tony Wied - Wikipedia[15]Wikipedia — Tom Tiffany - Wikipedia[6]Congress.gov — Rep. Kim Schrier — Congress.gov profile
Sources cited
  1. [1] 119th United States Congress - Wikipedia Wikipedia
  2. [2] US Rep. Brett Guthrie to lead House Energy and Commerce Committee AP News
  3. [3] Chairman Guthrie Announces 119th E&C Republican Subcommittee Assignments (includes Health Subcommittee) House Energy & Commerce Committee (Republicans)
  4. [4] Modernizing the Licensure Process - America’s Blood Centers America’s Blood Centers
  5. [5] CRS: The Legislative Process on the Senate Floor: An Introduction (96-548) Congressional Research Service (Congress.gov)
  6. [6] Rep. Kim Schrier — Congress.gov profile Congress.gov
  7. [7] CRS: Suspension of the Rules in the House: Principal Features (98-314) Congressional Research Service (Congress.gov)
  8. [8] DeGette announced as Top Democrat on E&C Health Subcommittee (119th) Office of Rep. Diana DeGette
  9. [9] Web search · turn 7 #4
  10. [10] AABB Regulatory Update: BLA checklist for apheresis plasma (supplements and comparability protocols) AABB
  11. [11] Cassidy seated as Chair of Senate HELP Committee (119th) Senate HELP Committee (Republicans)
  12. [12] STAT: HHS job cuts include 3,500 FDA layoffs STAT News
  13. [13] FDA unveils expedited review list under National Priority Voucher program AP News
  14. [14] Tony Wied - Wikipedia Wikipedia
  15. [15] Tom Tiffany - Wikipedia Wikipedia
  16. [16] Johnson refuses to swear in Grijalva amid shutdown standoff Politico
  17. [17] Scalise statement on being re‑elected House Majority Leader for the 119th Office of the House Majority Leader
  18. [18] GOP leader John Thune vows to preserve filibuster as Republicans retake Senate New York Post
  19. [19] Web search · turn 11 #0
  20. [20] FDA Guidance: Changes to an Approved Application—Human Blood and Blood Components (21 CFR 601.12) U.S. Food & Drug Administration

Discussion